Ngenla
What Ngenla is used for
Indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Ngenla
- Active substance
- somatrogon
- Disease area
- Growth and Development
- Medicine group
- PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
- ATC code
- H01AC08
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Ngenla
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ngenla used for?
Indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone
What is the active substance in Ngenla?
Ngenla contains somatrogon.
Who makes Ngenla?
The EU marketing authorisation holder is Pfizer Europe MA EEIG.
Is Ngenla an orphan medicine?
Yes. Ngenla is designated an orphan medicine in the EU, for a rare disease (Growth and Development).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU